Close
Back to ETTX Stock Lookup
Pages: 1 2 3 4 »» Last Page

(ETTX) – Press Releases

Oct 12, 2022 08:30 AM Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
Jul 8, 2022 08:35 AM Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
Jun 9, 2022 08:00 AM Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
Jun 9, 2022 08:00 AM Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
May 24, 2022 04:04 PM ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm
May 23, 2022 08:30 AM Innoviva to Acquire Entasis Therapeutics
May 23, 2022 08:30 AM Innoviva to Acquire Entasis Therapeutics
May 23, 2022 08:30 AM Innoviva to Acquire Entasis Therapeutics
May 17, 2022 08:00 AM Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
May 17, 2022 08:00 AM Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Apr 27, 2022 05:11 PM Innoviva Reports First Quarter 2022 Financial Results
Apr 27, 2022 07:30 AM Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
Apr 27, 2022 07:30 AM Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
Apr 26, 2022 08:00 AM Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Apr 26, 2022 08:00 AM Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference
Apr 18, 2022 08:30 AM Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
Apr 18, 2022 08:30 AM Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
Mar 3, 2022 07:30 AM Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
Mar 3, 2022 07:30 AM Entasis Therapeutics Announces Year End 2021 Financial Results and Provides Business Update
Feb 2, 2022 04:33 PM Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
Feb 2, 2022 04:33 PM Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
Jan 10, 2022 08:00 AM Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
Jan 10, 2022 08:00 AM Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
Nov 4, 2021 07:30 AM Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Nov 4, 2021 07:30 AM Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
Oct 28, 2021 08:00 AM Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
Oct 28, 2021 08:00 AM Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021
Oct 19, 2021 09:00 AM Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
Oct 19, 2021 09:00 AM Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
Oct 18, 2021 04:05 PM Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
Oct 18, 2021 04:05 PM Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
Sep 23, 2021 04:05 PM Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 23, 2021 04:05 PM Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 15, 2021 04:01 PM Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
Sep 15, 2021 04:01 PM Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
Sep 9, 2021 08:00 AM Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 9, 2021 08:00 AM Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 11, 2021 04:05 PM Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 11, 2021 04:05 PM Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 10, 2021 08:00 AM Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
Aug 10, 2021 08:00 AM Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
Aug 5, 2021 04:01 PM Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
Aug 5, 2021 04:01 PM Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
Aug 4, 2021 04:05 PM Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Aug 4, 2021 04:05 PM Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Jul 28, 2021 04:05 PM Innoviva Reports Second Quarter 2021 Financial Results
Jul 27, 2021 08:00 AM Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
Jul 27, 2021 08:00 AM Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam
Jul 14, 2021 08:00 AM Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
Jul 14, 2021 08:00 AM Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
Pages: 1 2 3 4 »» Last Page

Back to ETTX Stock Lookup